Monopar Therapeutics Inc. Annual report [Section 13 and 15(d), not S-K Item 405]

Annual report [Section 13 and 15(d), not S-K Item 405]

Note 2 - Significant Accounting Policies (Tables)

Note 2 - Significant Accounting Policies (Tables)

12 Months Ended

Dec. 31, 2025

Notes Tables

Fair Value Measurements, Recurring and Nonrecurring [Table Text Block]

As of December 31, 2025		*Level 1*				*Total*
Assets:
Cash equivalents⁽¹⁾		$	60,875,969			$	60,875,969
Total		$	60,875,969			$	60,875,969

As of December 31, 2024		*Level 1*				*Total*
Assets:
Cash equivalents⁽¹⁾		$	45,531,646			$	45,531,646
Total		$	45,531,646			$	45,531,646